Substandard and falsified ivermectin tablets obtained for self‐medication during the COVID‐19 pandemic as a source of potential harm
Drug Testing and Analysis · 2024
DOI: 10.1002/dta.3618 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Testing and Analysis, 2024. Verfasst von Celine Vanhee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Service Medicines and Health Products, Scientific Direction of Chemical and Physical Health Risks, Sciensano, Brussels, Belgium. Hauptthemen laut MEDLINE: Ivermectin, Tablets, Self Medication, Counterfeit Drugs. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 78 Literaturangaben.
Abstract (Originalsprache)
In 2019, a global viral pandemic, due to the SARS‐CoV‐2 virus, broke out. Soon after, the search for a vaccine and/or antiviral medicine began. One of the candidate antiviral medicines tested was ivermectin. Although several health authorities warned the public against the use of this medicine outside clinical trials, the drug was widely used at the end of 2020 and in 2021. Simultaneously, several reports started to emerge demonstrating serious adverse effects after self‐medicating with ivermectin. It stands to reason that the self‐administration of substandard or falsified (SF) medicines bearing harmful quality deficiencies have contributed to this phenomenon. In order to have a better view on the nature of these harmful quality deficiencies, SF ivermectin samples, intercepted in large quantities by the Belgian regulatory agencies during the period 2021–2022, were analyzed in our official medicines control laboratory. None of the samples ( n = 19) were compliant to the quality criteria applicable to medicinal products. These SF products either suffered from a systematic underdosing of the active pharmaceutical ingredient or were severely contaminated with bacteria, two of which were contaminated with known pathogens that cause gastrointestinal illness upon oral intake. In addition to the direct risks of self‐medicating with such a product, the improper usage and dosage of ivermectin medication might also facilitate ivermectin tolerance or resistance in parasites. This may have detrimental consequences on a global scale, certainly as the number of newly developed active pharmaceutical ingredients that can safely be used to combat parasites is rather scarce.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service Medicines and Health Products, Scientific Direction of Chemical and Physical Health Risks, Sciensano, Brussels, Belgium.
- Service of Foodborne Pathogen, Scientific Direction of Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
- Federal Agency for Medicine and Health Care Products, Brussels, Belgium.
ORCID-Profile: Celine Vanhee, Bram Jacobs
Zitieren
APA
Vanhee, C., Jacobs, B., Kamugisha, A., Canfyn, M., Van Der Meersch, H., Ceyssens, B., Deconinck, E., Van Hoorde, K., & Willocx, M. (2024). Substandard and falsified ivermectin tablets obtained for self‐medication during the COVID‐19 pandemic as a source of potential harm. Drug Testing and Analysis. https://doi.org/10.1002/dta.3618
Vancouver
Vanhee C, Jacobs B, Kamugisha A, Canfyn M, Van Der Meersch H, Ceyssens B, et al. Substandard and falsified ivermectin tablets obtained for self‐medication during the COVID‐19 pandemic as a source of potential harm. Drug Testing and Analysis. 2024. doi:10.1002/dta.3618
BibTeX
@article{Vanhee2024,
author = {Vanhee, Celine and Jacobs, Bram and Kamugisha, Angélique and Canfyn, Michael and Van Der Meersch, Hans and Ceyssens, Bart and Deconinck, Eric and Van Hoorde, Koenraad and Willocx, Marie},
title = {Substandard and falsified ivermectin tablets obtained for self‐medication during the COVID‐19 pandemic as a source of potential harm},
journal = {Drug Testing and Analysis},
year = {2024},
doi = {10.1002/dta.3618}
}
EUVIMED